Reminder of Class Action for Mereo BioPharma ADS Purchasers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy MREO?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while these studies failed to meet primary endpoints, causing investors to buy ADS at inflated prices.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with proven success; Rosen Law Firm has a strong track record in securities class actions, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and resources in this field.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain counsel or remain absent, with their ability to share in any potential future recovery not dependent on serving as lead plaintiff, ensuring their rights are adequately protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.361
Low
0.50
Averages
2.08
High
5.00
Current: 0.361
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action for Mereo BioPharma ADS Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 6, 2026, to seek compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab, leading investors to purchase ADS at artificially inflated prices, resulting in damages when the truth emerged.
- Law Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to choose counsel with a proven track record to ensure optimal representation in the class action, avoiding firms that lack actual litigation experience and merely act as intermediaries.
See More
Class Action Filed Against Mereo BioPharma Group for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing significant adverse facts about its Phase 3 ORBIT and COSMIC programs, leading to investor misunderstandings that could negatively impact stock prices.
- Clinical Trial Failures: Mereo's two critical clinical trials failed to meet primary endpoints, specifically not reducing the annualized fracture rate compared to placebo or bisphosphonate control groups, which could adversely affect the company's future market performance and investor confidence.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff to share in any potential recovery from the lawsuit, underscoring the importance of legal proceedings in protecting investor rights.
See More
Mereo BioPharma Shareholder Class Action Notice
- Lawsuit Background: Shareholders of Mereo BioPharma Group plc who purchased shares between June 5, 2023, and December 26, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Mereo provided overly positive statements regarding the Phase 3 ORBIT and COSMIC programs while concealing the fact that neither study achieved its primary endpoints, misleading investors and impacting their decisions.
- Stock Price Plummet: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's stock price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Shareholder Action Steps: Shareholders must register for the class action by April 6, 2026, to participate, and upon registration, they will receive status updates throughout the case lifecycle, reflecting the company's commitment to shareholder rights.
See More
Mereo BioPharma Reports $41.9 Million FY Net Loss
- Financial Performance: Mereo BioPharma reported a net loss of $41.9 million for FY 2025, indicating high expenditures in R&D and operations that could impact future financing capabilities.
- Revenue Situation: The company generated only $500,000 in revenue during the same fiscal year, significantly below industry expectations, reflecting insufficient market acceptance of its products and potentially eroding investor confidence.
- Cash Flow Status: As of December 31, 2025, Mereo had cash and cash equivalents of $41.0 million, providing some liquidity; however, without significant revenue growth, the company may face cash flow pressures.
- Market Reaction: Mereo BioPharma's presentation at the J.P. Morgan Healthcare Conference failed to boost its stock price, indicating market concerns about its future prospects, which could hinder financing and partnership opportunities.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to ensure investor rights are protected.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, necessitating careful consideration of their next steps.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
See More
Reminder of Class Action for Mereo BioPharma ADS Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 6, 2026, to seek compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab, leading investors to purchase ADS at artificially inflated prices, resulting in damages when the truth emerged.
- Law Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to choose counsel with a proven track record to ensure optimal representation in the class action, avoiding firms that lack actual litigation experience and merely act as intermediaries.
See More
Class Action Filed Against Mereo BioPharma Group for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing significant adverse facts about its Phase 3 ORBIT and COSMIC programs, leading to investor misunderstandings that could negatively impact stock prices.
- Clinical Trial Failures: Mereo's two critical clinical trials failed to meet primary endpoints, specifically not reducing the annualized fracture rate compared to placebo or bisphosphonate control groups, which could adversely affect the company's future market performance and investor confidence.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff to share in any potential recovery from the lawsuit, underscoring the importance of legal proceedings in protecting investor rights.
See More
Mereo BioPharma Shareholder Class Action Notice
- Lawsuit Background: Shareholders of Mereo BioPharma Group plc who purchased shares between June 5, 2023, and December 26, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Mereo provided overly positive statements regarding the Phase 3 ORBIT and COSMIC programs while concealing the fact that neither study achieved its primary endpoints, misleading investors and impacting their decisions.
- Stock Price Plummet: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's stock price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Shareholder Action Steps: Shareholders must register for the class action by April 6, 2026, to participate, and upon registration, they will receive status updates throughout the case lifecycle, reflecting the company's commitment to shareholder rights.
See More
Mereo BioPharma Reports $41.9 Million FY Net Loss
- Financial Performance: Mereo BioPharma reported a net loss of $41.9 million for FY 2025, indicating high expenditures in R&D and operations that could impact future financing capabilities.
- Revenue Situation: The company generated only $500,000 in revenue during the same fiscal year, significantly below industry expectations, reflecting insufficient market acceptance of its products and potentially eroding investor confidence.
- Cash Flow Status: As of December 31, 2025, Mereo had cash and cash equivalents of $41.0 million, providing some liquidity; however, without significant revenue growth, the company may face cash flow pressures.
- Market Reaction: Mereo BioPharma's presentation at the J.P. Morgan Healthcare Conference failed to boost its stock price, indicating market concerns about its future prospects, which could hinder financing and partnership opportunities.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to ensure investor rights are protected.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, necessitating careful consideration of their next steps.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
See More
